Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 5/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4684682 | 0.94 | MGLL (0.50) | MGLLACHE | |
| Hydrochloric Acid SCHEMBL4679268 | 0.93 | MGLL (0.49) | MGLLACHE | |
| SCHEMBL4681022 | 0.91 | TPSAB1 (0.39) | ACHEMMP2MMP9MMP14FAAH | |
| Hydrochloric Acid SCHEMBL4681632 | 0.90 | TPSAB1 (0.38) | ACHEMMP2MMP9MMP14FAAH | |
| SCHEMBL4681041 | 0.89 | FAAH (0.39) | MGLLFAAH | |
| Hydrochloric Acid SCHEMBL4681138 | 0.88 | FAAH (0.38) | MGLLFAAH | |
| SCHEMBL4684855 | 0.85 | ALDH1A1 (0.48) | FAAH | |
| Hydrochloric Acid SCHEMBL4684401 | 0.84 | ALDH1A1 (0.47) | FAAH | |
| SCHEMBL5881504 | 0.83 | ITGB1 (0.39) | FAAHITGB1ITGA4ITGB7 | |
| SCHEMBL905850 | 0.83 | NPC1 (0.47) | MGLLACHEFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| US-7022707-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040235859-A1 | Novel piperazine derivatives | ADAMS DAVID REGINALD (GB) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235859-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | MGLL 3851/4885ACHE 2342/4885MMP2 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.